MA35449B1 - Molécules de liaison pour bcma et cd3 - Google Patents

Molécules de liaison pour bcma et cd3

Info

Publication number
MA35449B1
MA35449B1 MA36845A MA36845A MA35449B1 MA 35449 B1 MA35449 B1 MA 35449B1 MA 36845 A MA36845 A MA 36845A MA 36845 A MA36845 A MA 36845A MA 35449 B1 MA35449 B1 MA 35449B1
Authority
MA
Morocco
Prior art keywords
binding
binding molecule
relates
bcma
binding molecules
Prior art date
Application number
MA36845A
Other languages
English (en)
Inventor
Peter Kufer
Tobias Raum
Patrick Hoffmann
Roman Kischel
Ralf Lutterbuese
Doris Rau
Paul Adam
Eric Borges
Barbara Hebeis
Susanne Hipp
Original Assignee
Amgen Res Munich Gmbh
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47388493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35449(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Res Munich Gmbh, Boehringer Ingelheim Int filed Critical Amgen Res Munich Gmbh
Publication of MA35449B1 publication Critical patent/MA35449B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une molécule de liaison qui est au moins bispécifique, comprenant un premier et un second domaine de liaison, le premier domaine de liaison étant capable de se lier à un groupe 3 d'épitope de bcma et le second domaine de liaison étant capable de se lier au complexe récepteur cd3 de lymphocytes t. De plus, l'invention concerne une séquence d'acide nucléique codant pour la molécule de liaison, un vecteur comprenant ladite séquence d'acide nucléique et une cellule hôte transformée ou transfectée par ledit vecteur. De plus, l'invention concerne un procédé de production de la molécule de liaison de l'invention, une utilisation médicale de ladite molécule de liaison et une trousse comprenant ladite molécule de liaison.
MA36845A 2011-11-15 2014-03-21 Molécules de liaison pour bcma et cd3 MA35449B1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201161560149P 2011-11-15 2011-11-15
US201161560144P 2011-11-15 2011-11-15
US201161560183P 2011-11-15 2011-11-15
US201161560178P 2011-11-15 2011-11-15
US201161560162P 2011-11-15 2011-11-15
US201261651474P 2012-05-24 2012-05-24
US201261651486P 2012-05-24 2012-05-24
PCT/EP2012/072699 WO2013072406A1 (fr) 2011-11-15 2012-11-15 Molécules de liaison pour bcma et cd3

Publications (1)

Publication Number Publication Date
MA35449B1 true MA35449B1 (fr) 2014-09-01

Family

ID=47388493

Family Applications (2)

Application Number Title Priority Date Filing Date
MA36845A MA35449B1 (fr) 2011-11-15 2014-03-21 Molécules de liaison pour bcma et cd3
MA36846A MA35450B1 (fr) 2011-11-15 2014-03-21 Molécules de liaison pour bcma et cd3

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA36846A MA35450B1 (fr) 2011-11-15 2014-03-21 Molécules de liaison pour bcma et cd3

Country Status (40)

Country Link
US (8) US9150664B2 (fr)
EP (5) EP2780374B1 (fr)
JP (5) JP6378087B2 (fr)
KR (4) KR20140105758A (fr)
CN (3) CN104114578B (fr)
AP (1) AP2014007529A0 (fr)
AR (1) AR088883A1 (fr)
AU (1) AU2012327203A1 (fr)
BR (2) BR112014010630B1 (fr)
CA (2) CA2850591A1 (fr)
CL (1) CL2014001254A1 (fr)
CY (1) CY1122543T1 (fr)
DK (1) DK2780375T3 (fr)
EA (2) EA028162B1 (fr)
EC (2) ECSP14004829A (fr)
ES (2) ES2749451T3 (fr)
FR (1) FR23C1013I1 (fr)
GE (2) GEAP201813496A (fr)
HR (1) HRP20191697T1 (fr)
HU (1) HUE046682T2 (fr)
IL (3) IL232603B (fr)
LT (1) LT2780375T (fr)
MA (2) MA35449B1 (fr)
ME (1) ME03521B (fr)
MX (2) MX2014005851A (fr)
MY (1) MY189544A (fr)
PE (1) PE20141564A1 (fr)
PH (2) PH12014501076A1 (fr)
PL (1) PL2780375T3 (fr)
PT (1) PT2780375T (fr)
RS (1) RS59373B1 (fr)
SG (4) SG10201606484SA (fr)
SI (1) SI2780375T1 (fr)
SM (1) SMT201900627T1 (fr)
TN (2) TN2014000097A1 (fr)
TW (1) TWI679212B (fr)
UA (1) UA116766C2 (fr)
UY (2) UY34453A (fr)
WO (2) WO2013072415A1 (fr)
ZA (1) ZA201401615B (fr)

Families Citing this family (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG194399A1 (en) * 2008-10-01 2013-11-29 Amgen Res Munich Gmbh Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
RU2014138474A (ru) 2012-02-24 2016-04-10 СтемСентРкс, Инк. Новые модуляторы и способы применения
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EP2762496A1 (fr) * 2013-02-05 2014-08-06 EngMab AG Procédé pour la sélection d'anticorps contre BCMA
US9963513B2 (en) * 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
MX2015010682A (es) 2013-02-22 2016-05-31 Stemcentrx Inc Nuevos conjugados de anticuerpos y usos de los mismos.
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
PE20160674A1 (es) 2013-08-28 2016-07-21 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
SG11201602760YA (en) * 2013-10-09 2016-05-30 Res Dev Foundation Monoclonal olfml-3 antibodies and uses thereof
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
CN106459990B (zh) 2014-02-07 2021-06-01 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
WO2015127407A1 (fr) 2014-02-21 2015-08-27 Stemcentrx, Inc. Anticorps anti-dll3 et conjugués de médicaments destinés à être utilisés dans un mélanome
WO2015128653A2 (fr) * 2014-02-27 2015-09-03 Ucl Business Plc Ligand
CA2945620C (fr) * 2014-04-14 2022-12-06 Cellectis Recepteurs antigeniques chimeriques specifiques de bcma (cd269), utiles dans l'immunotherapie du cancer
KR20170010863A (ko) 2014-07-01 2017-02-01 화이자 인코포레이티드 이중특이성 이종이량체성 디아바디 및 이의 용도
EP2982692A1 (fr) 2014-08-04 2016-02-10 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
AU2015329966A1 (en) * 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1 for use in the treatment of ovarian cancer
EP3221356B1 (fr) 2014-11-20 2020-09-02 F.Hoffmann-La Roche Ag Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3
BR112017010513A2 (pt) * 2014-11-20 2018-04-03 F. Hoffmann-La Roche Ag ?cadeias leves comuns e métodos de uso?
EP3023437A1 (fr) * 2014-11-20 2016-05-25 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
EP3029068A1 (fr) 2014-12-03 2016-06-08 EngMab AG Anticorps bispécifiques contre du CD3epsilon et BCMA pour utilisation dans le traitement de maladies
SG11201704549UA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
EP3872094A3 (fr) * 2014-12-05 2021-12-08 Memorial Sloan Kettering Cancer Center Anticorps ciblant un antigène de maturation des lymphocytes b et procédés d'utilisation
KR102626448B1 (ko) * 2015-02-24 2024-01-19 더 유니버시티 오브 브리티시 콜롬비아 연속 흐름 미세유체 시스템
IL310723A (en) 2015-04-13 2024-04-01 Pfizer Therapeutic antibodies and their uses
TWI700298B (zh) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向ｂ細胞成熟抗原之嵌合型抗原受體類
US11046767B2 (en) * 2015-05-13 2021-06-29 Ablynx N.V. T cell recruiting polypeptides based on CD3 reactivity
BR112017024757A2 (pt) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr utilizando proteínas de fusão
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
AU2016302881B2 (en) * 2015-08-03 2022-09-15 Bristol-Myers Squibb Company Monoclonal antibodies against BCMA
KR20250008141A (ko) 2015-08-07 2025-01-14 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017031104A1 (fr) * 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations
EP4349997A3 (fr) 2015-09-24 2024-07-10 Daiichi Sankyo Company, Limited Anticorps anti-garp
DK3380522T5 (da) 2015-11-25 2024-09-30 Visterra Inc Antistofmolekyler til april og anvendelser deraf
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
CA3011942A1 (fr) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Constructions d'anticorps impliquant des cellules t bispecifiques psma et cd3
SG11201805770UA (en) * 2016-02-03 2018-08-30 Amgen Res Munich Gmbh BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
LT3433280T (lt) 2016-03-22 2023-07-10 F. Hoffmann-La Roche Ag Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
US10689450B2 (en) * 2016-04-01 2020-06-23 Kite Pharma, Inc BCMA binding molecules and methods of use thereof
US10550184B2 (en) 2016-04-11 2020-02-04 The Trustees Of Columbia University In The City Of New York Humanized anti-rage antibody
AU2017267793B2 (en) 2016-05-20 2024-01-25 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN109641049B (zh) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 Cd3结合抗体
WO2018014260A1 (fr) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
WO2018026953A1 (fr) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions et méthodes de reprogrammation de tcr en utilisant des protéines de fusion
KR102512934B1 (ko) 2016-08-10 2023-03-23 레전드 바이오테크 아일랜드 리미티드 Bcma를 표적으로 하는 키메라 항원 수용체 및 이들의 이용 방법
MY200988A (en) * 2016-09-14 2024-01-27 Teneobio Inc CD3 Binding Antibodies
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
WO2018068201A1 (fr) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique et ses variants contre ctla-4
EP3535295A1 (fr) 2016-11-02 2019-09-11 EngMab Sàrl Anticorps bispécifique contre bcma et cd3 et médicament immunologique pour une utilisation combinée dans le traitement du myélome multiple
AU2017357649A1 (en) * 2016-11-11 2019-05-23 Autolus Limited Chimeric antigen receptor
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
JP7685735B2 (ja) 2016-12-02 2025-05-30 アンヘレス セラピューティクス インコーポレイテッド 合成免疫受容体およびその使用方法
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
JP2020506700A (ja) 2017-01-31 2020-03-05 ノバルティス アーゲー 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
AU2018219348A1 (en) * 2017-02-10 2019-08-29 Dragonfly Therapeutics, Inc. Proteins binding BCMA, NKG2D and CD16
JP2020507605A (ja) 2017-02-17 2020-03-12 フレッド ハッチンソン キャンサー リサーチ センター Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
CA3051062C (fr) 2017-02-28 2023-09-26 Affimed Gmbh Di-anticorps en tandem pour la mise en contact de cellules nk dirigees par cd16a
WO2018160754A2 (fr) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Protéine monovalente inductible de fixation d' antigène
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
CA3063362A1 (fr) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Proteines trispecifiques ciblant la msln et procedes d'utilisation
IL312322B2 (en) 2017-06-20 2026-05-01 Teneobio Inc Antibodies against BCMA containing only heavy chains
WO2018237006A1 (fr) 2017-06-20 2018-12-27 Teneoone, Inc. Anticorps uniquement à chaînes lourdes anti-bcma
WO2019000223A1 (fr) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. Activateurs de cellules effectrices immunitaires d'anticorps chimériques et leurs procédés d'utilisation
TWI901940B (zh) 2017-08-03 2025-10-21 美商安進公司 介白素-21突變蛋白及治療方法
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
CN111051306B (zh) 2017-09-08 2023-01-03 美国安进公司 Kras g12c的抑制剂及其使用方法
JP2020533380A (ja) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌の組合せ治療
US20200254093A1 (en) 2017-09-14 2020-08-13 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
JP2020533382A (ja) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌の組合せ治療
JP7227630B2 (ja) 2017-10-12 2023-02-22 マックマスター ユニバーシティー Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
SI3694529T1 (sl) * 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
KR20200086278A (ko) 2017-10-18 2020-07-16 노파르티스 아게 선택적 단백질 분해를 위한 조성물 및 방법
CA3080904A1 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Anticorps et recepteurs antigeniques chimeriques specifiques de l'antigene de maturation des lymphocytes b
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
EP3706754A1 (fr) 2017-11-06 2020-09-16 Juno Therapeutics, Inc. Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
SG11202004512XA (en) 2017-11-15 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
WO2019108900A1 (fr) 2017-11-30 2019-06-06 Novartis Ag Récepteur d'antigène chimérique ciblant le bcma et ses utilisations
WO2019126756A1 (fr) 2017-12-22 2019-06-27 Teneobio, Inc. Anticorps à chaîne lourde se liant à cd22
BR112020013086A2 (pt) * 2017-12-27 2020-12-08 Teneobio, Inc. Anticorpos específicos de heterodímero de cd3-delta/épsilon
TW201930358A (zh) 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之單域抗體及其變異體
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
WO2019139987A1 (fr) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Constructions de liaison à la calréticuline et lymphocytes t modifiés pour le traitement de maladies
JP2019122373A (ja) 2018-01-12 2019-07-25 アムジエン・インコーポレーテツド 抗ｐｄ−１抗体及び治療方法
KR102839330B1 (ko) 2018-01-15 2025-07-30 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
WO2019147670A1 (fr) 2018-01-23 2019-08-01 Nextcure, Inc. Anticorps anti-b7-h4 et leurs procédés d'utilisation
AU2019215031C1 (en) 2018-01-31 2026-02-26 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019160956A1 (fr) 2018-02-13 2019-08-22 Novartis Ag Thérapie par récepteur antigénique chimérique en combinaison avec il-15 r et il15
CN112119099A (zh) 2018-03-02 2020-12-22 Cdr-生物科技股份有限公司 三特异性抗原结合蛋白
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN116836297A (zh) * 2018-04-12 2023-10-03 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
EP3774914A2 (fr) * 2018-04-13 2021-02-17 Affimed GmbH Constructions de fusion d'anticorps entrant en contact avec des cellules nk
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
SG11202011306TA (en) 2018-05-16 2020-12-30 Janssen Biotech Inc Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
AU2019277029C1 (en) * 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
EP3817772A4 (fr) 2018-06-08 2022-03-16 Imaginab, Inc. Constructions de liaison d'antigène à cd4
WO2020010250A2 (fr) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
MX2021000532A (es) 2018-07-19 2021-04-12 Regeneron Pharma Receptores antigénicos quiméricos con especificidad para bcma y usos de estos.
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
BR112020024074A2 (pt) 2018-07-20 2021-02-17 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd19
EP3830122A1 (fr) * 2018-07-31 2021-06-09 Amgen Research (Munich) GmbH Régime posologique pour anticorps bispécifiques bcma-cd3
EP3833392A4 (fr) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
RS65658B1 (sr) * 2018-08-27 2024-07-31 Affimed Gmbh Kriokonzervirane nk ćelije prethodno punjene konstruktom antitela
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
PT3844267T (pt) 2018-08-31 2025-09-30 Novartis Ag Métodos de preparação de células que expressam recetor de antigénio quimérico
WO2020047449A2 (fr) 2018-08-31 2020-03-05 Novartis Ag Procédés de fabrication de cellules exprimant un récepteur d'antigène chimère
PT3844189T (pt) 2018-08-31 2025-01-29 Regeneron Pharma Estratégia de dosagem que mitiga a síndrome de libertação de citocinas para anticorpos bisepecíficos contra cd3/c20
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (fr) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Protéines de liaison à dll3 et méthodes d'utilisation
AR116548A1 (es) 2018-09-28 2021-05-19 Amgen Inc Anticuerpos contra bcma soluble
CN109503716B (zh) * 2018-10-08 2021-04-27 浙江生研生物科技有限公司 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
US20220003772A1 (en) 2018-10-31 2022-01-06 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
JP7410143B2 (ja) 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2020229806A1 (en) 2019-02-25 2021-07-29 Novartis Ag Mesoporous silica particles compositions for viral delivery
US20230074800A1 (en) 2019-03-21 2023-03-09 Novartis Ag Car-t cell therapies with enhanced efficacy
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (fr) 2019-04-24 2022-03-02 Novartis AG Compositions et procédés de dégradation sélective de protéines
KR20220008866A (ko) 2019-05-14 2022-01-21 하푼 테라퓨틱스, 인크. EpCAM 결합 단백질 및 사용 방법
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
JP7665538B2 (ja) 2019-06-14 2025-04-21 テネオバイオ， インコーポレイテッド Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
CN110229232B (zh) 2019-06-19 2020-05-19 北京智仁美博生物科技有限公司 双特异性抗体及其用途
CN114286828A (zh) * 2019-06-24 2022-04-05 诺华股份有限公司 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
CN112204135B (zh) * 2019-07-06 2026-03-06 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
MX2022001626A (es) 2019-08-06 2022-03-02 Glaxosmithkline Ip Dev Ltd Composiciones biofarmaceuticas y procedimientos conexos.
JP2022548943A (ja) * 2019-09-25 2022-11-22 フェイト セラピューティクス，インコーポレイテッド 複数標的化エフェクター細胞およびその使用
EP4023673A4 (fr) * 2019-10-10 2023-03-15 Suzhou Qin Pharmaceuticals Co., Ltd. Anticorps monoclonal humanisé ciblant bcma et ayant une réactivité croisée singe/etre humain
SI3819007T1 (sl) 2019-11-11 2024-10-30 Amgen Inc. Režim odmerjanja sredstev proti BCMA
EP4065158A2 (fr) 2019-11-26 2022-10-05 Novartis AG Récepteurs antigéniques chimériques et leurs utilisations
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
CA3170833A1 (fr) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Proteines de liaison a flt3 et methodes d'utilisation
CN115175695A (zh) 2020-02-27 2022-10-11 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
MX2022010685A (es) 2020-02-27 2022-09-23 Novartis Ag Metodos de produccion de celulas que expresan receptores de antigeno quimericos.
MX2022011632A (es) 2020-03-19 2022-10-13 Amgen Inc Anticuerpos contra mucina 17 y usos de los mismos.
WO2021222578A1 (fr) 2020-04-29 2021-11-04 Teneobio, Inc. Anticorps à chaîne lourde multispécifiques ayant des régions constantes de chaîne lourde modifiées
IL297601A (en) 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
PH12022553023A1 (en) 2020-05-11 2024-03-04 Janssen Biotech Inc Methods for treating multiple myeloma
CN115666727A (zh) 2020-05-19 2023-01-31 詹森生物科技公司 包含t细胞重定向治疗剂和vla-4粘附途径抑制剂的组合物
CN116096862A (zh) 2020-06-11 2023-05-09 诺华股份有限公司 Zbtb32抑制剂及其用途
PE20230464A1 (es) 2020-06-30 2023-03-14 Teneobio Inc Union de anticuerpos multiespecificos a bcma
EP4202047A4 (fr) * 2020-08-20 2024-09-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Domaine structural variable unique de liaison à bcma et molécule de liaison à l'antigène
TW202227124A (zh) 2020-08-21 2022-07-16 瑞士商諾華公司 用於體內產生ｃａｒ表現細胞的組成物和方法
WO2022060901A1 (fr) 2020-09-16 2022-03-24 Amgen Inc. Méthodes d'administration de doses thérapeutiques de molécules bispécifiques activant les lymphocytes t pour le traitement du cancer
TW202233682A (zh) 2020-11-10 2022-09-01 美商安進公司 用於投與ＢＣＭＡｘＣＤ３結合分子之方法
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种t细胞衔接器治疗剂的开发和应用
WO2022135468A1 (fr) * 2020-12-23 2022-06-30 信达生物制药(苏州)有限公司 Anticorps bispécifique anti-bcma×cd3 et son utilisation
CN114763383B (zh) * 2021-01-13 2024-12-17 博生吉医药科技(苏州)有限公司 靶向人bcma的单克隆抗体及其应用
RS66868B1 (sr) 2021-01-28 2025-06-30 Regeneron Pharma Kompozicije i postupci za lečenje sindroma oslobađanja citokina
JP2024515591A (ja) 2021-04-08 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｔｃｒに結合する多機能性分子およびその使用
TW202309294A (zh) 2021-04-27 2023-03-01 瑞士商諾華公司 病毒載體生產系統
WO2022248870A1 (fr) 2021-05-28 2022-12-01 Glaxosmithkline Intellectual Property Development Limited Polythérapies pour traiter le cancer
EP4347660A4 (fr) 2021-06-01 2025-06-04 Triumvira Immunologics USA, Inc. Coupleurs d'antigène de lymphocytes t de claudine 18.2 et leurs utilisations
CN119569887A (zh) * 2021-06-24 2025-03-07 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
WO2023012669A2 (fr) 2021-08-03 2023-02-09 Glaxosmithkline Intellectual Property Development Limited Compositions biopharmaceutiques et procédé de cartographie peptidique de marquage isotopique stable
JP2024531364A (ja) 2021-08-20 2024-08-29 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
WO2023057893A1 (fr) 2021-10-05 2023-04-13 Glaxosmithkline Intellectual Property Development Limited Polythérapies pour le traitement du cancer
WO2023081705A1 (fr) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Méthodes de traitement de cancers et d'amélioration de l'efficacité d'anticorps bispécifiques bcmaxcd3
EP4469484A1 (fr) 2022-01-25 2024-12-04 GlaxoSmithKline Intellectual Property Development Ltd Polythérapie contre le cancer
CA3247475A1 (fr) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions et méthodes permettant la destruction de cellule tumorale universelle
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
CN120303298A (zh) 2022-12-05 2025-07-11 葛兰素史密斯克莱知识产权发展有限公司 使用b细胞成熟抗原拮抗剂的治疗方法
JP2026506095A (ja) 2023-02-17 2026-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３／ｔａａ二重特異性抗体に応答する誘導ｎｋ細胞
CN121263449A (zh) 2023-03-21 2026-01-02 拜格拉夫55公司 Cd19/cd38多特异性抗体
AU2024244733B2 (en) 2023-03-31 2025-12-11 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
KR20250170671A (ko) * 2023-04-11 2025-12-05 아벨제타 인크. Bcma 및 cd19를 표적화하는 이중특이적 키메라 항원 수용체
WO2024246083A1 (fr) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Anticorps bispécifiques ciblant bcma et cd28
WO2024246086A1 (fr) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Molécules de liaison à l'antigène immunostimulatrices se liant spécifiquement à bcma
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
US20250242018A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025174963A1 (fr) 2024-02-16 2025-08-21 Kite Pharma, Inc. Systèmes, procédés et kits pour la production et l'administration de lymphocytes t modifiés et de composés de ciblage de cd38 sous forme de polythérapie
WO2025184567A1 (fr) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Procédés et compositions pour redosage d'un aav à l'aide d'un anticorps antagoniste anti-cd40 pour supprimer une réponse d'anticorps anti-aav hôte
WO2026037514A1 (fr) * 2024-08-13 2026-02-19 Friedrich-Alexander-Universität Erlangen-Nürnberg, in Vertretung des Freistaates Bayern Agent de liaison bispécifique ciblant cd3 et bcma pour le traitement de maladies auto-immunes
WO2026050572A2 (fr) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Molécules multifonctionnelles se liant au tcr et leurs utilisations
WO2026072671A1 (fr) 2024-09-24 2026-04-02 City Of Hope Procédés utilisant des virus oncolytiques exprimant le bcmat et thérapies ciblées anti-bcma
WO2026094004A2 (fr) 2024-11-04 2026-05-07 Glaxosmithkline Intellectual Property Development Limited Traitement combiné pour un myélome multiple avec une protéine de liaison à l'antigène anti-bcma

Family Cites Families (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US70185A (en) 1867-10-29 fan oh be
US556A (en) 1838-01-09 Machine foe
US5013A (en) 1847-03-13 Improvement in apparatus for the manufacture of malleable iron
US4816A (en) 1846-10-17 Bell machinery for hotels
US2003A (en) 1841-03-12 Improvement in horizontal windivhlls
US1985A (en) 1841-02-18 Charles m
US567A (en) 1838-01-09 Machine for r-uibbii
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (fr) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Procede de fixation d'une proteine sur un substrat
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (fr) 1977-02-17 1981-01-20 Hideo Hirohara Traduction non-disponible
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4281061A (en) 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4475916A (en) 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
WO1987005330A1 (fr) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Procede pour ameliorer la stabilite des glycoproteines
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69032484D1 (de) 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3126980B2 (ja) 1991-03-11 2001-01-22 ザ・ユニバーシテイ・オブ・ジヨージア・リサーチ・フアウンデーシヨン・インコーポレーテツド レニラ（ｒｅｎｉｌｌａ）ルシフェラーゼのクローニング及び発現
WO1992022670A1 (fr) 1991-06-12 1992-12-23 Genpharm International, Inc. Detection precoce d'embryons transgeniques
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1992022645A1 (fr) 1991-06-14 1992-12-23 Genpharm International, Inc. Animaux transgeniques non humains presentant une deficience immunitaire
WO1993004169A1 (fr) 1991-08-20 1993-03-04 Genpharm International, Inc. Ciblage de genes dans des cellules animales au moyen de produits de synthese d'adn isogeniques
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
AU694745B2 (en) 1993-09-10 1998-07-30 Trustees Of Columbia University In The City Of New York, The Uses of green fluorescent protein
WO1995021191A1 (fr) 1994-02-04 1995-08-10 William Ward Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
EP0822830B1 (fr) 1995-04-27 2008-04-02 Amgen Fremont Inc. Anticorps anti-IL-8 dérivés de xenosouris immunisées
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
CA2230759C (fr) 1995-08-29 2012-02-21 Kirin Beer Kabushiki Kaisha Animal chimerique et procede pour le produire
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
WO1998026277A2 (fr) 1996-12-12 1998-06-18 Prolume, Ltd. Appareil permettant de detecter et d'identifier des agents infectieux et procede correspondant
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
WO1998052976A1 (fr) 1997-05-21 1998-11-26 Biovation Limited Procede de production de proteines non immunogenes
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
DE69837611T2 (de) 1997-10-01 2007-12-27 Boston Scientific Ltd., St. Michael Dilatationssysteme
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
US7074405B1 (en) 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
WO2000006605A2 (fr) 1998-07-28 2000-02-10 Micromet Ag Heterominicorps
EP1051432B1 (fr) 1998-12-08 2007-01-24 Biovation Limited Modification de l'immunogenicite de proteines
TR200101998T2 (tr) 1999-01-07 2002-06-21 Zymogenetics, Inc. Çözünür reseptör BR 43x2 ve kullanım metodları
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
PL211786B1 (pl) 1999-08-17 2012-06-29 Apoxis Sa Zastosowanie przeciwciała oraz polipeptydu
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
DE60128216T2 (de) 2000-05-12 2008-01-10 Amgen Inc., Thousand Oaks Polypeptide zum Hemmen der April-vermittelten Proliferation von B- und T- Zellen
PA8535501A1 (es) 2001-01-05 2003-07-28 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
CA2438682A1 (fr) * 2001-02-20 2002-08-29 Zymogenetics, Inc. Anticorps liant a la fois bcma et taci
WO2002100348A2 (fr) 2001-06-13 2002-12-19 Genmab A/S Anticorps monoclonaux humains diriges contre le recepteur de facteur de croissance epidermique (egfr)
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP3698626A1 (fr) 2001-11-30 2020-08-26 Amgen Fremont Inc. Animaux transgéniques portant des gènes à chaîne légère lambda ig humains
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体
AU2003223683A1 (en) 2002-04-22 2003-11-03 Georgetown University Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration
EP1629013B1 (fr) 2003-05-31 2018-01-24 Amgen Research (Munich) GmbH Composition pharmaceutique comprenant un anticorps bispecifique destinee a epcam
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
DK1629011T3 (da) 2003-05-31 2010-05-03 Micromet Ag Humane anti-humane-DC3-bindingsmolekyler
ZA200601699B (en) 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
EP1701979A2 (fr) 2003-12-03 2006-09-20 Xencor, Inc. Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique
WO2005077981A2 (fr) 2003-12-22 2005-08-25 Xencor, Inc. Polypeptides fc a nouveaux sites de liaison de ligands fc
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
JP4541014B2 (ja) 2004-01-13 2010-09-08 キヤノンアネルバ株式会社 プラズマ支援スパッタ成膜装置
EP1709072A1 (fr) * 2004-01-29 2006-10-11 Genentech, Inc. Variants du domaine extracellulaire de bcma et utilisations de ceux-ci
BRPI0507649A (pt) * 2004-02-16 2007-07-10 Micromet Ag molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit
US20050265993A1 (en) 2004-04-06 2005-12-01 Bernard Mach Methods of treating autoimmune and inflammatory diseases
MXPA06014075A (es) 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
WO2006031370A2 (fr) 2004-08-19 2006-03-23 Genentech, Inc. Variants de polypeptides dotes d'une fonction effectrice modifiee
WO2006138181A2 (fr) 2005-06-14 2006-12-28 Amgen Inc. Preparations de proteines a tamponnage spontane
AU2006267090B2 (en) 2005-07-11 2013-03-07 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
AR057807A1 (es) 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
CN101370830A (zh) * 2005-09-26 2009-02-18 米德列斯公司 抗cd70的人单克隆抗体
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
US20090226466A1 (en) 2005-11-03 2009-09-10 Sherman Fong Therapeutic anti-her2 antibody fusion polypeptides
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
US20230357444A1 (en) 2007-04-03 2023-11-09 Amgen Research (Munich) Gmbh Cross-species-specific binding domain
CN109456410B (zh) 2007-04-03 2022-01-28 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
US20100183615A1 (en) 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
SG10201808730VA (en) 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
CA2682605A1 (fr) 2007-04-18 2008-10-30 Zymogenetics, Inc. Fc a chaine simple, procedes de fabrication et procedes de traitement
US7998018B2 (en) 2007-04-30 2011-08-16 GM Global Technology Operations LLC Multi-speed transmission
EP2158318A2 (fr) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Régions fc simple chaîne, polypeptides de liaison comportant de telles régions, et procédés correspondants
CA2720682A1 (fr) * 2008-04-25 2009-10-29 Zymogenetics, Inc. Niveaux d'expression de la proteine bcma sur les lymphocytes b et utilisation dans de methodes diagnostiques
EP4180458A1 (fr) 2008-10-01 2023-05-17 Amgen Research (Munich) GmbH Anticorps bispécifique à chaîne unique psma x cd3 particulière d'une espèce à l'autre
SG194399A1 (en) 2008-10-01 2013-11-29 Amgen Res Munich Gmbh Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
CA2738568C (fr) 2008-10-01 2024-02-20 Micromet Ag Anticorps monocatenaire bispecifique a domaine unique, specifique d'especes croisees
JP2012509658A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド Ｉｌ−１３に結合するリガンド
KR101589785B1 (ko) 2009-03-10 2016-01-28 바이오젠 엠에이 인코포레이티드 항-ｂｃｍａ 항체
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
ES2674567T3 (es) 2010-05-21 2018-07-02 Merrimack Pharmaceuticals, Inc. Proteínas de fusión biespecíficas
US9410994B2 (en) 2010-11-15 2016-08-09 Lg Electronics Inc. Refrigerator and operation method thereof
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
EP2655624B1 (fr) 2010-12-23 2017-11-29 Biogen MA Inc. Peptides coupleurs et polypeptides les comportant
SI3415531T1 (sl) 2011-05-27 2023-12-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) - vezni proteini
US20130078250A1 (en) 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
EP3321286B1 (fr) 2011-08-23 2021-01-06 Roche Glycart AG Molécules bispécifiques de liaison à l'antigène activant des lymphocytes t
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US20140154253A1 (en) 2012-07-13 2014-06-05 Zymeworks Inc. Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2731280B8 (fr) 2012-11-07 2019-03-20 Telefonaktiebolaget LM Ericsson (publ) Auto-test intégré en bouclage local
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
CA2898100C (fr) 2013-01-14 2023-10-10 Xencor, Inc. Nouvelles proteines heterodimeres
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
EP2762497A1 (fr) 2013-02-05 2014-08-06 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
CA2902505A1 (fr) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anticorps bispecifiques anti-c-met a fc en tandem
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
EP2970449B1 (fr) 2013-03-15 2019-09-25 Amgen Research (Munich) GmbH Molécules de liaison à chaîne simple comprenant l'abp à l'extrémité n-terminale
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
EP3049440B1 (fr) 2013-09-25 2020-03-25 Amgen Inc. Anticorps v-c-fc-v-c
JP6749312B2 (ja) 2014-07-31 2020-09-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 最適化された種間特異的二重特異性単鎖抗体コンストラクト
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
SG11201704283PA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
DK3283524T3 (da) 2015-04-17 2023-05-30 Amgen Res Munich Gmbh BISPECIFIKKE ANTISTOFKONSTRUKTIONER MOD CDH3 og CD3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
SG11201805770UA (en) 2016-02-03 2018-08-30 Amgen Res Munich Gmbh BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
CA3011942A1 (fr) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Constructions d'anticorps impliquant des cellules t bispecifiques psma et cd3
EP3535295A1 (fr) 2016-11-02 2019-09-11 EngMab Sàrl Anticorps bispécifique contre bcma et cd3 et médicament immunologique pour une utilisation combinée dans le traitement du myélome multiple
KR102700015B1 (ko) 2017-05-05 2024-08-29 암젠 인크 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
JP2014534242A (ja) 2014-12-18
BR112014010630A2 (pt) 2017-04-25
US12281176B2 (en) 2025-04-22
WO2013072415A1 (fr) 2013-05-23
ECSP14004829A (es) 2015-07-31
ES2751996T3 (es) 2020-04-02
TN2014000097A1 (en) 2015-07-01
IL232636A0 (en) 2014-06-30
KR20200003934A (ko) 2020-01-10
BR112014010940A2 (pt) 2017-05-16
JP2017195889A (ja) 2017-11-02
EP2780375B1 (fr) 2019-09-11
NZ622087A (en) 2016-06-24
SMT201900627T1 (it) 2020-01-14
US20130156770A1 (en) 2013-06-20
EP2780374B1 (fr) 2019-08-21
CN104114578B (zh) 2018-10-16
ECSP14004893A (es) 2015-06-30
EA201490931A1 (ru) 2014-08-29
SG10201606484SA (en) 2016-10-28
PT2780375T (pt) 2019-11-12
MX2014005852A (es) 2014-09-22
UY34454A (es) 2013-06-28
GEAP201813496A (en) 2018-07-10
KR102062231B1 (ko) 2020-01-03
EP2780375A1 (fr) 2014-09-24
EP4512481A2 (fr) 2025-02-26
US20150023967A1 (en) 2015-01-22
CY1122543T1 (el) 2021-01-27
ME03521B (fr) 2020-04-20
CL2014001254A1 (es) 2014-10-10
US20140348837A1 (en) 2014-11-27
AR088883A1 (es) 2014-07-16
BR112014010630B1 (pt) 2022-10-04
SG11201401729PA (en) 2014-09-26
US20130156769A1 (en) 2013-06-20
CA2849196C (fr) 2021-04-20
EP3623385A1 (fr) 2020-03-18
JP2018050627A (ja) 2018-04-05
KR102229469B1 (ko) 2021-03-18
WO2013072406A1 (fr) 2013-05-23
MX349396B (es) 2017-07-26
CA2849196A1 (fr) 2013-05-23
IL232603A0 (en) 2014-06-30
KR20210032012A (ko) 2021-03-23
JP6378087B2 (ja) 2018-08-22
MA35450B1 (fr) 2014-09-01
UY34453A (es) 2013-06-28
GEP20186928B (en) 2018-11-26
US9340621B2 (en) 2016-05-17
US12281175B2 (en) 2025-04-22
CN104114578A (zh) 2014-10-22
TN2014000121A1 (en) 2015-07-01
CN104169300A (zh) 2014-11-26
US20220064336A1 (en) 2022-03-03
SI2780375T1 (sl) 2019-11-29
SG10201704483RA (en) 2017-07-28
US20220356268A1 (en) 2022-11-10
AP2014007529A0 (en) 2014-03-31
IL260189A (en) 2018-07-31
EP2780374A1 (fr) 2014-09-24
EP3623385A8 (fr) 2020-05-06
US9150664B2 (en) 2015-10-06
JP6738314B2 (ja) 2020-08-12
PH12014501091A1 (en) 2014-07-28
IL232603B (en) 2018-07-31
RS59373B1 (sr) 2019-11-29
JP2020202838A (ja) 2020-12-24
MY189544A (en) 2022-02-16
EA201490932A1 (ru) 2014-09-30
FR23C1013I1 (fr) 2023-04-14
US20220251243A1 (en) 2022-08-11
UA116766C2 (uk) 2018-05-10
EA028162B1 (ru) 2017-10-31
JP6231007B2 (ja) 2017-11-15
PE20141564A1 (es) 2014-11-29
CA2850591A1 (fr) 2013-05-23
US9598500B2 (en) 2017-03-21
KR102346029B1 (ko) 2022-01-03
JP7250736B2 (ja) 2023-04-03
HRP20191697T1 (hr) 2019-12-13
ZA201401615B (en) 2017-08-30
TW201326214A (zh) 2013-07-01
LT2780375T (lt) 2019-11-11
EP3611193A1 (fr) 2020-02-19
US10766969B2 (en) 2020-09-08
ES2749451T3 (es) 2020-03-20
PH12014501076A1 (en) 2014-06-23
JP2015504306A (ja) 2015-02-12
SG11201400671YA (en) 2014-04-28
MX2014005851A (es) 2015-01-19
PL2780375T3 (pl) 2020-01-31
AU2012327203A1 (en) 2013-05-30
HUE046682T2 (hu) 2020-03-30
EP4512481A3 (fr) 2025-03-12
CN109485729A (zh) 2019-03-19
KR20140105757A (ko) 2014-09-02
DK2780375T3 (da) 2019-11-18
TWI679212B (zh) 2019-12-11
KR20140105758A (ko) 2014-09-02
US20250346684A1 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
MA35450B1 (fr) Molécules de liaison pour bcma et cd3
EP3912997A3 (fr) Molécules de liaison pour bcma et cd3
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
MA38400A1 (fr) Molécules fc bispécifiques
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
CY1122399T1 (el) Αγωνιστικοι παραγοντες δεσμευσης του υποδοχεα tnf
EP2647706A4 (fr) Molécule de liaison à l'antigène, apte à se lier de façon répétée à une pluralité de molécules d'antigène
Kuznetsov et al. Critical review of existing MHC I immunopeptidome isolation methods
JOP20190009A1 (ar) أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
Bobkov et al. Antibodies targeting chemokine receptors CXCR4 and ACKR3
MA37894A1 (fr) Protéines de fusion d'interleukine-2 et leurs utilisations
EA200800229A1 (ru) Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1)
MX358862B (es) Diseño de anticuerpo heterodimérico estable con mutaciones en el domino fc.
MX384198B (es) Proteina de fusion que comprende tres dominios de union a 5t4 y cd3.
MA37619A1 (fr) Anticorps anti-fcrn
BR112013023006A8 (pt) formulações de suspensões não aquosas de anticorpos de alta concentração e viscosidade reduzida
FR3034430B1 (fr) Lignee cellulaire surexprimant l'antigene cd303 humain
EP2625317A4 (fr) Systèmes et procédés électrochimiques pour le fonctionnement d'une cellule électrochimique dans un anolyte acide
BR112014001979A2 (pt) uso do anticorpo i-3859 para a detecção e diagnóstico de câncer
FR2976800B1 (fr) Composition cosmetique comprenant au moins un compose organique du silicium et au moins un polymere amphotere particulier
CL2014001263A1 (es) Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes.
Komura et al. Syntheses of Bifunctional Photoaffinity Ganglioside Probes for Studying Raft-associated Interactions.
BR112014024192A2 (pt) epítopos de antígeno superficial do receptor de fator de crescimento epidérmico e uso desses
MA38331A1 (fr) Constructions d'anticorps liants cdh19 et cd3 humains pour une utilisation dans le traitement de melanome metastatique
Lin et al. TCR-T Cell Recognition of an NY-ESO-1 Epitope Presented by HLA-A2 Supertype: Implications for Cancer Immunotherapy